MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial.

Por Thomas Pavelitz, Lindsay Renfro, Nathan R Foster, Amber Caracol, Piri Welsch, Victoria Valinluck Lao, William B Grady, Donna Niedzwiecki, Leonard B Saltz, Monica M Bertagnolli, Richard M Goldberg, Peter S Rabinovitch, Mary Emond, Raymond J Monnat, Nancy Maizels
Publicado em 2014-01-01